Lymphocyte subpopulations in melanoma patients treated with dendritic cell vaccines.
The main goal of cancer immunotherapy is to induce or boost tumor-specific effector cells able to eliminate or reduce tumor progression. In this study, we characterized lymphocyte phenotypes in melanoma patients receiving dendritic cell (DC)-based vaccinotherapy. We found that several biological markers served as unfavorable prognostic factors for patients' response to therapy. This included decrease of CD4+ and CD8+ lymphocyte levels, 10% and higher increase of CD16+CD3+CD8+ lymphocyte population, and increase of CD16+CD8+perforin+ T lymphocytes, especially in combination with decreased levels of CDI6+CD8(-)perforin+ and CD8+CD16(-)perforin+ cells. Increase in CD8+CD16(-)perforin+ T lymphocytes with normal levels of CD16+CD8(-)perforin+ cells and the absence of CD16+CD8+perforin+ and regulatory lymphocytes were shown to be the positive prognostic markers for patients' response to DC vaccines.
Kadagidze
Zaira G
ZG
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia. kad-zaira@yandex.ru
Borunova
Anna A
AA
Zabotina
Tatiana N
TN
D017252:CD3 Complex / Q000096:biosynthesis; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism; D019496:Cancer Vaccines / Q000737:chemistry*; D003713:Dendritic Cells / Q000166:cytology*; D018450:Disease Progression; D018572:Disease-Free Survival; D005434:Flow Cytometry; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016131:Lymphocyte Subsets / Q000166:cytology*; D008214:Lymphocytes / Q000378:metabolism; D008545:Melanoma / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*; D010641:Phenotype; D017452:Receptors, IgG / Q000096:biosynthesis
D017252:CD3 Complex; D019496:Cancer Vaccines; D017452:Receptors, IgG